SH‐PRO extract alleviates benign prostatic hyperplasia via ROS‐mediated activation of PARP/caspase 3 and inhibition of FOXO3a/AR/PSA signaling in vitro and in vivo

To target benign prostatic hyperplasia (BPH) as a common urinary disease in old men, in the current study, the antiproliferative and apoptotic mechanism of SH‐PRO, a mixture of Angelica gigas and Astragalus membranaceus (2:1), was evaluated in BPH‐1 cells and rats with testosterone‐induced BPH. Here...

Full description

Saved in:
Bibliographic Details
Published in:Phytotherapy research 2023-02, Vol.37 (2), p.452-463
Main Authors: Park, Ji Eon, Shin, Woo‐Cheol, Lee, Hyo‐Jung, Yoon, Dahye, Sim, Deok Yong, Ahn, Chi‐Hoon, Park, Su‐Yeon, Shim, Bum Sang, Park, So Jung, Kim, Kyung Seok, Park, Geum Duck, Kim, Sung‐Hoon, Lee, Dae Young
Format: Article
Language:English
Subjects:
Acetylcysteine
Androgen receptors
Animals
Antigens
Antiproliferatives
Apoptosis
Astragalus membranaceus
benign ptatic hyperplasia
Biocompatibility
Caspase 3
Caspases
Catalase
Dihydrotestosterone
Fibroblast growth factor 2
FOXO3 protein
FOXO3a
Humans
Hyperplasia
Male
Plant Extracts - therapeutic use
Plasma levels
Poly(ADP-ribose) polymerase
Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use
Prostate
Prostate-Specific Antigen
Prostatic Hyperplasia - chemically induced
Prostatic Hyperplasia - drug therapy
Rats
Reactive oxygen species
Reactive Oxygen Species - adverse effects
Receptors, Androgen - metabolism
ros
SH‐PRO
Signaling
Testosterone
Testosterone - adverse effects
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To target benign prostatic hyperplasia (BPH) as a common urinary disease in old men, in the current study, the antiproliferative and apoptotic mechanism of SH‐PRO, a mixture of Angelica gigas and Astragalus membranaceus (2:1), was evaluated in BPH‐1 cells and rats with testosterone‐induced BPH. Herein, SH‐PRO significantly reduced the viability of BPH‐1 cells and dihydrotestosterone (DHT)‐treated RWPE‐1 cells. Also, SH‐PRO increased the sub‐G1 population in BPH‐1 cells and consistently attenuated the expression of pro‐PARP, pro‐caspase 3, Bcl2, FOXO3a, androgen receptor (AR), and prostate‐specific antigen (PSA) in BPH‐1 cells and DHT‐treated RWPE‐1 cells. Of note, SH‐PRO generated reactive oxygen species (ROS) in BPH‐1 cells, while ROS inhibitor N‐acetyl‐l‐cysteine (NAC) disturbed the ability of SH‐PRO to reduce the expression of pro‐PARP, FOXO3a, catalase, SOD, and increase sub‐G1 population in BPH‐1 cells. Furthermore, oral treatment of SH‐PRO significantly abrogated the weight of the prostate in testosterone‐treated rats compared to BPH control with the reduced expression of AR, PSA, and DHT and lower plasma levels of DTH, bFGF, and EGF with no toxicity. Overall, these findings highlight the antiproliferative and apoptotic potential of SH‐PRO via ROS‐mediated activation of PARP and caspase 3 and inhibition of FOXO3a/AR/PSA signaling as a potent anti‐BPH candidate.
ISSN:0951-418X
1099-1573
DOI:10.1002/ptr.7626